Search Results
Feb 02, 2026, 09:36 ET CoreAge Rx Responds to Winter Storm Fern Shipping Delays
USPS reported significant delays, with service suspensions in thousands of ZIP codes. CoreAge Rx, a leading telehealth provider specializing in GLP-1 weight management medications, is responding to widespread shipping disruptions caused by the severe winter storm currently affecting much of the United
More news about: CoreAge Rx
Feb 02, 2026, 08:43 ET ANIMAL on the Training and Performance Trends Shaping 2026
protein continue to lead the category, supported by better formats, smarter pairing, and broader everyday use. Recovery focused ingredients, GLP-1 related support, and mental performance are gaining attention as athletes focus on muscle preservation, output quality, and consistency."These
More news about: ANIMAL
Feb 02, 2026, 07:37 ET SJM Sambut Tahun Kuda dengan Penuh Berkah dan Keberuntungan
Parade Tahun Baru Imlek yang digelar Macao Government Tourism Office pada malam 19 dan 28 Februari. Selain itu, keluarga dapat berkreasi bersama dalam GLP Arte setiap akhir pekan hingga 28 Februari, membuat angpao, tanaman hias dari kawat berbulu, atau kincir angin keberuntungan.Spot
More news about: SJM Resorts, S.A.
Feb 01, 2026, 08:20 ET SJM chào đón năm Ngọ với sự thịnh vượng và may mắn
Đán của Sở Du lịch Chính quyền Ma Cao vào các tối ngày 19 và 28 tháng 2. Bên cạnh đó, các gia đình có thể cùng nhau gắn kết qua sự sáng tạo tại xưởng GLP Arte vào cuối tuần, kéo dài từ nay đến ngày 28 tháng 2, để tự tay làm bao lì xì cá nhân hóa, chậu cây làm từ dây kẽm xù, hay chong chóng may mắn.
More news about: SJM Resorts, S.A.
Jan 30, 2026, 11:00 ET Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, a first-in-class investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. This is the
More news about: Eli Lilly and Company
Jan 30, 2026, 03:47 ET 全球首個偏向型GLP-1埃諾格魯肽注射液獲批
藥品監督管理局（NMPA）批准，用於成人2型糖尿病患者的血糖控制，並成為全球首個獲批上市的cAMP偏向型GLP-1受體激動劑。 近年來，我國糖尿病患者數量持續攀升，截至2024年，這一群體規模已達約1.48億人。同時，糖尿病的治療理念也在不斷升級，治療目標從單純的血糖控制，逐步拓展為兼顧降低心血管風險、保護器官功能的長期綜合獲益。GLP-1受體激動劑作為成人2型糖尿病的核心治療藥物之一，憑借分子設計的持續迭代，進而研發出以埃諾格魯肽為代表的 「偏向型GLP-1RA」，標志著糖尿病精準治療的全新方向，已得到《中國糖尿病防治指南（2024版）》的權威認可。
More news about: 杭州先為達生物科技股份有限公司
Jan 29, 2026, 10:02 ET Milliways® Plastic Free Chewing Gum Brand Raises $3 Million to Accelerate US Growth
changing faster than ever. The power of AI and social media means people are better informed, more curious, and quicker to adopt new habits. Whether it's GLP-1s, longevity hacks, or plastic-free chewing gum, the desire to live healthier lives is now at the top of everyone's agenda. And it's not just the big
More news about: Milliways
Jan 29, 2026, 09:00 ET Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy
treatments has been surging, with a market size projected to reach USD 60.53 billion by 2030, yet latest therapies including GLP-1 receptor agonists (GLP-1RAs) still face challenges represented by lean mass loss, efficacy plateaus, rapid weight regain upon withdrawal, and patient adherence.
More news about: Insilico Medicine
Jan 29, 2026, 06:00 ET Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
a once-monthly subcutaneously administered amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
More news about: Ascletis Pharma Inc.
Jan 28, 2026, 10:00 ET Maeva Launches Science-Backed Nutrition Line Designed Exclusively for GLP-1 Users
approach designed to complement GLP-1 lifestyles in ways traditional meal replacements, protein powders, and supplements are not specifically designed to address. Co-founder Steven Neiger says, "Maeva was born out of personal experience. After taking GLP-1s, I saw firsthand how easy it was to
More news about: Maeva
Jan 28, 2026, 09:22 ET CONSCIOUS CAPITAL GROWTH AND PETRA CAPITAL PARTNERS ACQUIRE RD NUTRITION CONSULTANTS, A LEADING NATIONAL CLINICAL NUTRITION PLATFORM
partners and multi-site healthcare operators. These services include dietary counseling and ongoing nutritional support for patients using GLP-1 medications, helping improve adherence, outcomes, and long-term sustainability of treatment.Heather Elrod, Managing Partner at Conscious
More news about: Conscious Capital Growth
Jan 28, 2026, 09:00 ET RO DEBUTS FIRST-EVER SUPER BOWL COMMERCIAL STARRING SERENA WILLIAMS TO LAUNCH "HEALTHIER ON RO" CAMPAIGN
first-ever Super Bowl commercial starring its GLP-1 patient ambassador, Serena Williams. The commercial marks the launch of "Healthier on Ro," a new national campaign spanning TV, digital and out-of-home, designed to highlight the benefits of GLP-1s including weight loss and other health biomarkers.
More news about: Ro
Jan 28, 2026, 08:37 ET New Peer-Reviewed Publication Validates Exceptional Safety and Efficacy of Synovetin OA® for Dog Arthritis
192892341.Doerr, CA, Bendele, A, Simon, J, Stevenson, N, and Gonzales, G. Validation of the use of homogeneous Sn-117m colloid radiosynoviorthesis in a GLP osteoarthritis rat model. J Nucl Med. (2016) 57:323.Doerr C, et al. Poster presented at the Society of Nuclear Medicine & Molecular
More news about: Exubrion Therapeutics
Jan 28, 2026, 08:05 ET Extra Weight Sneaks Up on Pets Too
About GLP-1 Treatments for PetsWith increased attention on GLP-1 weight-loss medications for humans, veterinarians say some pet owners ask whether similar options exist for their pets."At this time, there are no FDA-approved GLP-1 weight-loss drugs
More news about: Thrive Pet Healthcare
Jan 28, 2026, 08:00 ET Newsweek and BrandSpark International announce the 18th annual 2026 Best New Product Awards winners spotlighting the new products that stand out to Americans
Supergut GLP-1 Daily SupportGLP-1 Support Supplements
More news about: Best New Product Awards Inc.
Jan 28, 2026, 01:23 ET Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity
philosophy of cause-focused, personalized medicine.A Complementary Strategy to Current Metabolic TherapiesCurrent therapies such as GLP-1 and amylin agonists have demonstrated strong efficacy in inducing rapid weight loss during the acute and subacute phases of treatment. TPC-026 is being
More news about: TETRAPHARM
Jan 28, 2026, 01:16 ET Promising Preclinical Data Support TPC-026 as a Novel Chronic Therapy for Metabolic Disorders Including Obesity
cause-focused, personalized medicine.A Complementary Strategy to Current Metabolic TherapiesCurrent therapies such as GLP-1 and amylin agonists have demonstrated strong efficacy in inducing rapid weight loss during the acute and subacute phases of treatment. TPC-026 is
More news about: TETRAPHARM
Jan 27, 2026, 23:21 ET Hanmi firma un acuerdo de exportación con su socio mexicano Sanfer para el fármaco GLP-1 contra la obesidad, junto con otros productos
28 de enero de 2026 /PRNewswire/ -- Hanmi acelera su entrada al mercado mundial con efpeglenatide, el primer tratamiento de clase GLP-1 contra la obesidad y las enfermedades metabólicas desarrollado de forma independiente en Corea.
More news about: Hanmi Pharmaceutical
Jan 27, 2026, 23:21 ET Hanmi assina acordo de exportação com a parceira mexicana Sanfer para o medicamento GLP-1 para obesidade, junto com outros produtos
de janeiro de 2026 /PRNewswire/ -- A Hanmi está acelerando sua entrada no mercado global com a efpeglenatide, o primeiro tratamento da classe GLP-1 desenvolvido internamente na Coreia para obesidade e doenças metabólicas.
More news about: Hanmi Pharmaceutical
Jan 27, 2026, 23:08 ET Hanmi Secures Export Deal with Mexican Partner Sanfer for GLP-1 Obesity Drug and More
Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
More news about: Hanmi Pharmaceutical
Jan 27, 2026, 21:48 ET Badan Pengawas Obat dan Makanan Amerika Serikat (FDA) Setujui Pil GLP‑1 Pertama untuk Manajemen Berat Badan, Tawarkan Efektivitas Setara Suntikan
demikian, pengelolaan obesitas melalui terapi GLP‑1 tidak hanya berkaitan dengan penampilan fisik, tetapi juga perlindungan terhadap kesehatan jantung dan membantu seseorang untuk hidup lebih lama."Pil GLP-1 kini telah hadir. Dengan persetujuan untuk terapi GLP-1 oral sekali sehari dari Novo Nordisk,
More news about: Novo Nordisk
Jan 27, 2026, 12:00 ET Frontage Europe Has Relocated Its Bioanalytical Laboratory and Further Expands Its Capabilities
assays were recently expanded with the acquisition of the Lumipulse G1200 instrument.The laboratory operates under Good Laboratory Practice (GLP) quality system and complies with Good Clinical Practice (GCP) to support clinical studies. Bioanalytical assay validation and sample analysis are performed
More news about: Frontage Laboratories, Inc.
Jan 27, 2026, 09:00 ET Debut Unveils Biotech Active Delivering In-Office Skin Tightening Results in Topical Skincare
tightening across the face, jawline and neck is rising due to a convergence of trends: new advances in aesthetic science, the rise of GLP-1-related rapid weight loss leading to skin laxity, and a consumer preference for natural-looking tautness over volume.DermCeutical EDL™ expands
More news about: Debut Biotechnology
Jan 27, 2026, 09:00 ET Asthma and Allergy Drug Development Is Failing Too Often--A Translational Reset Is Needed: HKEY-AIRx™1.0
protection, with clear IP frameworks defined at project inception. These foundational practices are built on ISO 9001 certification, adherence to GLP principles, AAALAC accreditation, and are validated by over 500 successful IND submissions. This is what enables us to deliver not just data, but
More news about: HKeyBio
Jan 27, 2026, 03:30 ET Die Entwicklung von Medikamenten gegen Asthma und Allergien ist häufig nicht erfolgreich -- es bedarf daher einer Neuausrichtung der translationalen Forschung: HKEY-AIRx™1.0
Jahren Erfahrung des Kernteams hat es weltweit mehr als 500 IND-Anträge unterstützt. Auf der Grundlage der ISO 9001-Zertifizierung, der Einhaltung der GLP-Grundsätze und der AAALAC-Akkreditierung bietet HKeyBio effiziente, konforme Lösungen, um die Entwicklung von Arzneimitteln für die klinische Anwendung
More news about: HKeyBio